{"id":8641,"date":"2023-05-17T11:00:59","date_gmt":"2023-05-17T09:00:59","guid":{"rendered":"https:\/\/www.afaf.asso.fr\/?p=8641"},"modified":"2023-05-17T11:01:01","modified_gmt":"2023-05-17T09:01:01","slug":"cti-1601-donnees-preliminaires-publiees-par-larimar-therapeutics","status":"publish","type":"post","link":"https:\/\/www.afaf.asso.fr\/2023\/05\/17\/cti-1601-donnees-preliminaires-publiees-par-larimar-therapeutics\/","title":{"rendered":"CTI-1601: Donn\u00e9es pr\u00e9liminaires publi\u00e9es par Larimar Therapeutics"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">Larimar Therapeutics a publi\u00e9 un communiqu\u00e9 de presse et un avis d&#8217;une diffusion web et d&#8217;une conf\u00e9rence t\u00e9l\u00e9phonique. Pour \u00e9couter, cliquez ici : <a href=\"https:\/\/bit.ly\/3nZ5AHW?fbclid=IwAR19GXsRi4hj3edX-lNudKfxtTFYrCd41vNFRERObfeXH6XD_JcWj7tYFpY\" target=\"_blank\" rel=\"noreferrer noopener\">https:\/\/bit.ly\/3nZ5AHW<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Continuez \u00e0 lire pour un r\u00e9sum\u00e9 du communiqu\u00e9 de presse ou cliquez ici pour le texte int\u00e9gral : <a href=\"https:\/\/bit.ly\/42D7P2J?fbclid=IwAR1CDrPDfufol4B6SvFY8W6r55RvJzDsWWJe8u1bx_yqptP-wg5gODhZd8M\" target=\"_blank\" rel=\"noreferrer noopener\">https:\/\/bit.ly\/42D7P2J<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Larimar Therapeutics rapporte les donn\u00e9es pr\u00e9liminaires de la cohorte de 25 mg de l&#8217;essai de phase 2 montrant des augmentations des niveaux de frataxine chez les patients atteints de l&#8217;ataxie de Friedreich et les r\u00e9sultats financiers du premier trimestre 2023<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\u2022 Les donn\u00e9es sur l&#8217;innocuit\u00e9 indiquent que les injections sous-cutan\u00e9es r\u00e9p\u00e9t\u00e9es de 25 mg CTI-1601 \u00e9taient g\u00e9n\u00e9ralement bien tol\u00e9r\u00e9es lorsqu&#8217;elles \u00e9taient administr\u00e9es tous les jours pendant 14 jours, puis tous les autres jours par la suite jusqu&#8217;au 28<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\u2022 Des injections sous-cutan\u00e9es quotidiennes de 25 mg CTI-1601 pendant 14 jours ont entra\u00een\u00e9 une augmentation des taux de frataxine par rapport au placebo dans tous les tissus \u00e9valu\u00e9s (peau et cellules buccales)<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\u2022 Augmentations m\u00e9dianes ajust\u00e9es en fonction du placebo par rapport aux valeurs de base de 3,5 pg\/ \u03bcg et 0,9 pg\/ \u03bcg des taux de frataxine observ\u00e9s dans la peau et les cellules buccales, respectivement, avec 14 jours de posologie quotidienne de CTI-1601<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\u2022 Larimar a soumis des donn\u00e9es \u00e0 la FDA et rencontrera l&#8217;Agence pour discuter des prochaines \u00e9tapes; mise \u00e0 jour attendue au T3 2023<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Larimar Therapeutics a publi\u00e9 un communiqu\u00e9 de presse et un avis d&#8217;une diffusion web et d&#8217;une conf\u00e9rence t\u00e9l\u00e9phonique. Pour \u00e9couter, cliquez ici : https:\/\/bit.ly\/3nZ5AHW Continuez \u00e0 lire pour un r\u00e9sum\u00e9 du communiqu\u00e9 de presse ou cliquez ici pour le texte int\u00e9gral : https:\/\/bit.ly\/42D7P2J Larimar Therapeutics rapporte les donn\u00e9es pr\u00e9liminaires de la cohorte de 25 mg [&hellip;]<\/p>\n","protected":false},"author":8,"featured_media":7805,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_monsterinsights_skip_tracking":false,"ocean_front_end_style_editor":"no","ocean_post_layout":"","ocean_both_sidebars_style":"","ocean_both_sidebars_content_width":0,"ocean_both_sidebars_sidebars_width":0,"ocean_sidebar":"0","ocean_second_sidebar":"0","ocean_disable_margins":"enable","ocean_add_body_class":"","ocean_shortcode_before_top_bar":"","ocean_shortcode_after_top_bar":"","ocean_shortcode_before_header":"","ocean_shortcode_after_header":"","ocean_has_shortcode":"","ocean_shortcode_after_title":"","ocean_shortcode_before_footer_widgets":"","ocean_shortcode_after_footer_widgets":"","ocean_shortcode_before_footer_bottom":"","ocean_shortcode_after_footer_bottom":"","ocean_display_top_bar":"default","ocean_display_header":"default","ocean_header_style":"","ocean_center_header_left_menu":"0","ocean_custom_header_template":"0","ocean_custom_logo":0,"ocean_custom_retina_logo":0,"ocean_custom_logo_max_width":0,"ocean_custom_logo_tablet_max_width":0,"ocean_custom_logo_mobile_max_width":0,"ocean_custom_logo_max_height":0,"ocean_custom_logo_tablet_max_height":0,"ocean_custom_logo_mobile_max_height":0,"ocean_header_custom_menu":"0","ocean_menu_typo_font_family":"0","ocean_menu_typo_font_subset":"","ocean_menu_typo_font_size":0,"ocean_menu_typo_font_size_tablet":0,"ocean_menu_typo_font_size_mobile":0,"ocean_menu_typo_font_size_unit":"px","ocean_menu_typo_font_weight":"","ocean_menu_typo_font_weight_tablet":"","ocean_menu_typo_font_weight_mobile":"","ocean_menu_typo_transform":"","ocean_menu_typo_transform_tablet":"","ocean_menu_typo_transform_mobile":"","ocean_menu_typo_line_height":0,"ocean_menu_typo_line_height_tablet":0,"ocean_menu_typo_line_height_mobile":0,"ocean_menu_typo_line_height_unit":"","ocean_menu_typo_spacing":0,"ocean_menu_typo_spacing_tablet":0,"ocean_menu_typo_spacing_mobile":0,"ocean_menu_typo_spacing_unit":"","ocean_menu_link_color":"","ocean_menu_link_color_hover":"","ocean_menu_link_color_active":"","ocean_menu_link_background":"","ocean_menu_link_hover_background":"","ocean_menu_link_active_background":"","ocean_menu_social_links_bg":"","ocean_menu_social_hover_links_bg":"","ocean_menu_social_links_color":"","ocean_menu_social_hover_links_color":"","ocean_disable_title":"default","ocean_disable_heading":"default","ocean_post_title":"","ocean_post_subheading":"","ocean_post_title_style":"","ocean_post_title_background_color":"","ocean_post_title_background":0,"ocean_post_title_bg_image_position":"","ocean_post_title_bg_image_attachment":"","ocean_post_title_bg_image_repeat":"","ocean_post_title_bg_image_size":"","ocean_post_title_height":0,"ocean_post_title_bg_overlay":0.5,"ocean_post_title_bg_overlay_color":"","ocean_disable_breadcrumbs":"default","ocean_breadcrumbs_color":"","ocean_breadcrumbs_separator_color":"","ocean_breadcrumbs_links_color":"","ocean_breadcrumbs_links_hover_color":"","ocean_display_footer_widgets":"default","ocean_display_footer_bottom":"default","ocean_custom_footer_template":"0","ocean_post_oembed":"","ocean_post_self_hosted_media":"","ocean_post_video_embed":"","ocean_link_format":"","ocean_link_format_target":"self","ocean_quote_format":"","ocean_quote_format_link":"post","ocean_gallery_link_images":"off","ocean_gallery_id":[],"footnotes":""},"categories":[43],"tags":[],"class_list":["post-8641","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-informations_recherche","entry","has-media","owp-thumbs-layout-horizontal","owp-btn-normal","owp-tabs-layout-section","has-no-thumbnails"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.1 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>CTI-1601: Donn\u00e9es pr\u00e9liminaires publi\u00e9es par Larimar Therapeutics - Association Fran\u00e7aise Ataxie de Friedreich<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.afaf.asso.fr\/2023\/05\/17\/cti-1601-donnees-preliminaires-publiees-par-larimar-therapeutics\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CTI-1601: Donn\u00e9es pr\u00e9liminaires publi\u00e9es par Larimar Therapeutics - Association Fran\u00e7aise Ataxie de Friedreich\" \/>\n<meta property=\"og:description\" content=\"Larimar Therapeutics a publi\u00e9 un communiqu\u00e9 de presse et un avis d&#8217;une diffusion web et d&#8217;une conf\u00e9rence t\u00e9l\u00e9phonique. Pour \u00e9couter, cliquez ici : https:\/\/bit.ly\/3nZ5AHW Continuez \u00e0 lire pour un r\u00e9sum\u00e9 du communiqu\u00e9 de presse ou cliquez ici pour le texte int\u00e9gral : https:\/\/bit.ly\/42D7P2J Larimar Therapeutics rapporte les donn\u00e9es pr\u00e9liminaires de la cohorte de 25 mg [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.afaf.asso.fr\/2023\/05\/17\/cti-1601-donnees-preliminaires-publiees-par-larimar-therapeutics\/\" \/>\n<meta property=\"og:site_name\" content=\"Association Fran\u00e7aise Ataxie de Friedreich\" \/>\n<meta property=\"article:published_time\" content=\"2023-05-17T09:00:59+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-05-17T09:01:01+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.afaf.asso.fr\/wp-content\/uploads\/2022\/12\/NEWS_actualite-scientifiques.png\" \/>\n\t<meta property=\"og:image:width\" content=\"3552\" \/>\n\t<meta property=\"og:image:height\" content=\"2365\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Caroline Gaboriau\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"Caroline Gaboriau\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.afaf.asso.fr\\\/2023\\\/05\\\/17\\\/cti-1601-donnees-preliminaires-publiees-par-larimar-therapeutics\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.afaf.asso.fr\\\/2023\\\/05\\\/17\\\/cti-1601-donnees-preliminaires-publiees-par-larimar-therapeutics\\\/\"},\"author\":{\"name\":\"Caroline Gaboriau\",\"@id\":\"https:\\\/\\\/www.afaf.asso.fr\\\/#\\\/schema\\\/person\\\/7366aa03c1779ab28140e42231ed7b28\"},\"headline\":\"CTI-1601: Donn\u00e9es pr\u00e9liminaires publi\u00e9es par Larimar Therapeutics\",\"datePublished\":\"2023-05-17T09:00:59+00:00\",\"dateModified\":\"2023-05-17T09:01:01+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.afaf.asso.fr\\\/2023\\\/05\\\/17\\\/cti-1601-donnees-preliminaires-publiees-par-larimar-therapeutics\\\/\"},\"wordCount\":252,\"publisher\":{\"@id\":\"https:\\\/\\\/www.afaf.asso.fr\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/www.afaf.asso.fr\\\/2023\\\/05\\\/17\\\/cti-1601-donnees-preliminaires-publiees-par-larimar-therapeutics\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.afaf.asso.fr\\\/wp-content\\\/uploads\\\/2022\\\/12\\\/NEWS_actualite-scientifiques-e1741791418735.png\",\"articleSection\":[\"Informations sur la recherche\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.afaf.asso.fr\\\/2023\\\/05\\\/17\\\/cti-1601-donnees-preliminaires-publiees-par-larimar-therapeutics\\\/\",\"url\":\"https:\\\/\\\/www.afaf.asso.fr\\\/2023\\\/05\\\/17\\\/cti-1601-donnees-preliminaires-publiees-par-larimar-therapeutics\\\/\",\"name\":\"CTI-1601: Donn\u00e9es pr\u00e9liminaires publi\u00e9es par Larimar Therapeutics - Association Fran\u00e7aise Ataxie de Friedreich\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.afaf.asso.fr\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.afaf.asso.fr\\\/2023\\\/05\\\/17\\\/cti-1601-donnees-preliminaires-publiees-par-larimar-therapeutics\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.afaf.asso.fr\\\/2023\\\/05\\\/17\\\/cti-1601-donnees-preliminaires-publiees-par-larimar-therapeutics\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.afaf.asso.fr\\\/wp-content\\\/uploads\\\/2022\\\/12\\\/NEWS_actualite-scientifiques-e1741791418735.png\",\"datePublished\":\"2023-05-17T09:00:59+00:00\",\"dateModified\":\"2023-05-17T09:01:01+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.afaf.asso.fr\\\/2023\\\/05\\\/17\\\/cti-1601-donnees-preliminaires-publiees-par-larimar-therapeutics\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.afaf.asso.fr\\\/2023\\\/05\\\/17\\\/cti-1601-donnees-preliminaires-publiees-par-larimar-therapeutics\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.afaf.asso.fr\\\/2023\\\/05\\\/17\\\/cti-1601-donnees-preliminaires-publiees-par-larimar-therapeutics\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.afaf.asso.fr\\\/wp-content\\\/uploads\\\/2022\\\/12\\\/NEWS_actualite-scientifiques-e1741791418735.png\",\"contentUrl\":\"https:\\\/\\\/www.afaf.asso.fr\\\/wp-content\\\/uploads\\\/2022\\\/12\\\/NEWS_actualite-scientifiques-e1741791418735.png\",\"width\":3552,\"height\":2362},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.afaf.asso.fr\\\/2023\\\/05\\\/17\\\/cti-1601-donnees-preliminaires-publiees-par-larimar-therapeutics\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\\\/\\\/www.afaf.asso.fr\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CTI-1601: Donn\u00e9es pr\u00e9liminaires publi\u00e9es par Larimar Therapeutics\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.afaf.asso.fr\\\/#website\",\"url\":\"https:\\\/\\\/www.afaf.asso.fr\\\/\",\"name\":\"Association Fran\u00e7aise Ataxie de Friedreich\",\"description\":\"Association Fran\u00e7aise de l&#039;Ataxie de Friedreich\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.afaf.asso.fr\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.afaf.asso.fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.afaf.asso.fr\\\/#organization\",\"name\":\"Association Fran\u00e7aise Ataxie de Friedreich\",\"url\":\"https:\\\/\\\/www.afaf.asso.fr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.afaf.asso.fr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.afaf.asso.fr\\\/wp-content\\\/uploads\\\/2022\\\/06\\\/Logo-vert.png\",\"contentUrl\":\"https:\\\/\\\/www.afaf.asso.fr\\\/wp-content\\\/uploads\\\/2022\\\/06\\\/Logo-vert.png\",\"width\":1181,\"height\":709,\"caption\":\"Association Fran\u00e7aise Ataxie de Friedreich\"},\"image\":{\"@id\":\"https:\\\/\\\/www.afaf.asso.fr\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.afaf.asso.fr\\\/#\\\/schema\\\/person\\\/7366aa03c1779ab28140e42231ed7b28\",\"name\":\"Caroline Gaboriau\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/8dbf8226706683015a2752bfbf4ecf0bea399e33452121cb9c1f4640fbea214f?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/8dbf8226706683015a2752bfbf4ecf0bea399e33452121cb9c1f4640fbea214f?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/8dbf8226706683015a2752bfbf4ecf0bea399e33452121cb9c1f4640fbea214f?s=96&d=mm&r=g\",\"caption\":\"Caroline Gaboriau\"},\"url\":\"https:\\\/\\\/www.afaf.asso.fr\\\/author\\\/caroline_gaboriau\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"CTI-1601: Donn\u00e9es pr\u00e9liminaires publi\u00e9es par Larimar Therapeutics - Association Fran\u00e7aise Ataxie de Friedreich","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.afaf.asso.fr\/2023\/05\/17\/cti-1601-donnees-preliminaires-publiees-par-larimar-therapeutics\/","og_locale":"fr_FR","og_type":"article","og_title":"CTI-1601: Donn\u00e9es pr\u00e9liminaires publi\u00e9es par Larimar Therapeutics - Association Fran\u00e7aise Ataxie de Friedreich","og_description":"Larimar Therapeutics a publi\u00e9 un communiqu\u00e9 de presse et un avis d&#8217;une diffusion web et d&#8217;une conf\u00e9rence t\u00e9l\u00e9phonique. Pour \u00e9couter, cliquez ici : https:\/\/bit.ly\/3nZ5AHW Continuez \u00e0 lire pour un r\u00e9sum\u00e9 du communiqu\u00e9 de presse ou cliquez ici pour le texte int\u00e9gral : https:\/\/bit.ly\/42D7P2J Larimar Therapeutics rapporte les donn\u00e9es pr\u00e9liminaires de la cohorte de 25 mg [&hellip;]","og_url":"https:\/\/www.afaf.asso.fr\/2023\/05\/17\/cti-1601-donnees-preliminaires-publiees-par-larimar-therapeutics\/","og_site_name":"Association Fran\u00e7aise Ataxie de Friedreich","article_published_time":"2023-05-17T09:00:59+00:00","article_modified_time":"2023-05-17T09:01:01+00:00","og_image":[{"width":3552,"height":2365,"url":"https:\/\/www.afaf.asso.fr\/wp-content\/uploads\/2022\/12\/NEWS_actualite-scientifiques.png","type":"image\/png"}],"author":"Caroline Gaboriau","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"Caroline Gaboriau","Dur\u00e9e de lecture estim\u00e9e":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.afaf.asso.fr\/2023\/05\/17\/cti-1601-donnees-preliminaires-publiees-par-larimar-therapeutics\/#article","isPartOf":{"@id":"https:\/\/www.afaf.asso.fr\/2023\/05\/17\/cti-1601-donnees-preliminaires-publiees-par-larimar-therapeutics\/"},"author":{"name":"Caroline Gaboriau","@id":"https:\/\/www.afaf.asso.fr\/#\/schema\/person\/7366aa03c1779ab28140e42231ed7b28"},"headline":"CTI-1601: Donn\u00e9es pr\u00e9liminaires publi\u00e9es par Larimar Therapeutics","datePublished":"2023-05-17T09:00:59+00:00","dateModified":"2023-05-17T09:01:01+00:00","mainEntityOfPage":{"@id":"https:\/\/www.afaf.asso.fr\/2023\/05\/17\/cti-1601-donnees-preliminaires-publiees-par-larimar-therapeutics\/"},"wordCount":252,"publisher":{"@id":"https:\/\/www.afaf.asso.fr\/#organization"},"image":{"@id":"https:\/\/www.afaf.asso.fr\/2023\/05\/17\/cti-1601-donnees-preliminaires-publiees-par-larimar-therapeutics\/#primaryimage"},"thumbnailUrl":"https:\/\/www.afaf.asso.fr\/wp-content\/uploads\/2022\/12\/NEWS_actualite-scientifiques-e1741791418735.png","articleSection":["Informations sur la recherche"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/www.afaf.asso.fr\/2023\/05\/17\/cti-1601-donnees-preliminaires-publiees-par-larimar-therapeutics\/","url":"https:\/\/www.afaf.asso.fr\/2023\/05\/17\/cti-1601-donnees-preliminaires-publiees-par-larimar-therapeutics\/","name":"CTI-1601: Donn\u00e9es pr\u00e9liminaires publi\u00e9es par Larimar Therapeutics - Association Fran\u00e7aise Ataxie de Friedreich","isPartOf":{"@id":"https:\/\/www.afaf.asso.fr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.afaf.asso.fr\/2023\/05\/17\/cti-1601-donnees-preliminaires-publiees-par-larimar-therapeutics\/#primaryimage"},"image":{"@id":"https:\/\/www.afaf.asso.fr\/2023\/05\/17\/cti-1601-donnees-preliminaires-publiees-par-larimar-therapeutics\/#primaryimage"},"thumbnailUrl":"https:\/\/www.afaf.asso.fr\/wp-content\/uploads\/2022\/12\/NEWS_actualite-scientifiques-e1741791418735.png","datePublished":"2023-05-17T09:00:59+00:00","dateModified":"2023-05-17T09:01:01+00:00","breadcrumb":{"@id":"https:\/\/www.afaf.asso.fr\/2023\/05\/17\/cti-1601-donnees-preliminaires-publiees-par-larimar-therapeutics\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.afaf.asso.fr\/2023\/05\/17\/cti-1601-donnees-preliminaires-publiees-par-larimar-therapeutics\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.afaf.asso.fr\/2023\/05\/17\/cti-1601-donnees-preliminaires-publiees-par-larimar-therapeutics\/#primaryimage","url":"https:\/\/www.afaf.asso.fr\/wp-content\/uploads\/2022\/12\/NEWS_actualite-scientifiques-e1741791418735.png","contentUrl":"https:\/\/www.afaf.asso.fr\/wp-content\/uploads\/2022\/12\/NEWS_actualite-scientifiques-e1741791418735.png","width":3552,"height":2362},{"@type":"BreadcrumbList","@id":"https:\/\/www.afaf.asso.fr\/2023\/05\/17\/cti-1601-donnees-preliminaires-publiees-par-larimar-therapeutics\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/www.afaf.asso.fr\/"},{"@type":"ListItem","position":2,"name":"CTI-1601: Donn\u00e9es pr\u00e9liminaires publi\u00e9es par Larimar Therapeutics"}]},{"@type":"WebSite","@id":"https:\/\/www.afaf.asso.fr\/#website","url":"https:\/\/www.afaf.asso.fr\/","name":"Association Fran\u00e7aise Ataxie de Friedreich","description":"Association Fran\u00e7aise de l&#039;Ataxie de Friedreich","publisher":{"@id":"https:\/\/www.afaf.asso.fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.afaf.asso.fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.afaf.asso.fr\/#organization","name":"Association Fran\u00e7aise Ataxie de Friedreich","url":"https:\/\/www.afaf.asso.fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.afaf.asso.fr\/#\/schema\/logo\/image\/","url":"https:\/\/www.afaf.asso.fr\/wp-content\/uploads\/2022\/06\/Logo-vert.png","contentUrl":"https:\/\/www.afaf.asso.fr\/wp-content\/uploads\/2022\/06\/Logo-vert.png","width":1181,"height":709,"caption":"Association Fran\u00e7aise Ataxie de Friedreich"},"image":{"@id":"https:\/\/www.afaf.asso.fr\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/www.afaf.asso.fr\/#\/schema\/person\/7366aa03c1779ab28140e42231ed7b28","name":"Caroline Gaboriau","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/secure.gravatar.com\/avatar\/8dbf8226706683015a2752bfbf4ecf0bea399e33452121cb9c1f4640fbea214f?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/8dbf8226706683015a2752bfbf4ecf0bea399e33452121cb9c1f4640fbea214f?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/8dbf8226706683015a2752bfbf4ecf0bea399e33452121cb9c1f4640fbea214f?s=96&d=mm&r=g","caption":"Caroline Gaboriau"},"url":"https:\/\/www.afaf.asso.fr\/author\/caroline_gaboriau\/"}]}},"_links":{"self":[{"href":"https:\/\/www.afaf.asso.fr\/api-afaf\/wp\/v2\/posts\/8641","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.afaf.asso.fr\/api-afaf\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.afaf.asso.fr\/api-afaf\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.afaf.asso.fr\/api-afaf\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/www.afaf.asso.fr\/api-afaf\/wp\/v2\/comments?post=8641"}],"version-history":[{"count":0,"href":"https:\/\/www.afaf.asso.fr\/api-afaf\/wp\/v2\/posts\/8641\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.afaf.asso.fr\/api-afaf\/wp\/v2\/media\/7805"}],"wp:attachment":[{"href":"https:\/\/www.afaf.asso.fr\/api-afaf\/wp\/v2\/media?parent=8641"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.afaf.asso.fr\/api-afaf\/wp\/v2\/categories?post=8641"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.afaf.asso.fr\/api-afaf\/wp\/v2\/tags?post=8641"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}